Fetuses Destined For Abortion May Be Used To Test Gene Therapy

CONTROVERSIAL plans to treat unborn children with gene therapy have been given an even more contentious twist. Under a proposal presented to a US government panel late last month, this therapy would initially be tested on fetuses destined for abortion.

Earlier this year, French Anderson of the University of Southern California in Los Angeles announced that he was seeking approval for fetal gene therapy (This Week, 27 June, p 12). He is still developing the techniques and will not be ready to start trials for at least three years. "We wanted to leave time for lots of public and private discussions," he says.

Anderson pioneered human gene therapy in 1990, when he treated children with a hereditary disorder called severe combined immune deficiency (SCID), caused by the lack of an enzyme vital for the development of the immune system. At a meeting of the National Institutes of Health Recombinant DNA Advisory Committee (RAC) on 24 September, Anderson described how fetuses with SCID would be given healthy copies of the gene for the enzyme. He also outlined plans for in utero treatment of an inherited blood disease called alpha-thalassaemia, caused by a defect in the gene for part of the oxygen-carrying molecule haemoglobin.

One concern is that a fetus's small size means the therapeutic gene has a greater chance of invading reproductive tissue and introducing genetic changes that will be passed down the generations.

But the committee had particular concerns about alpha-thalassaemia, says Claudia Mickleson, biosafety officer at the Massachusetts Institute of Technology and chair of the RAC. We each carry four copies of the gene that is defective in people with alpha-thalassaemia. In the worst cases all four copies are damaged and fetuses die in the womb or shortly after birth. The mother can also develop a life-threatening condition called pre-eclampsia, which involves high blood pressure and fluid retention. "If the therapy

Contact: Claire Bowles
44 171 331 2751
New Scientist

Page: 1 2

Related biology news :

1. Major Heart Defects Can Be Identified In Fetuses By 14 Weeks Of Gestation
2. 1st International Conference on Cell Therapy for Cardiovascular Disease
3. National Cancer Gene Therapy Foundation gives $4.0 million in research grants
4. Braunschweig Prize 2003 for Molecular Cancer Therapy
5. Alliance for Cancer Gene Therapy announces $1.5 million in national grants to young investigators
6. New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy
7. Therapy hinders AIDS virus from evolving drug resistance, Hopkins researchers find
8. Invitation To Cover: American Society Of Gene Therapy Meeting
9. Gene Therapy For Pain
10. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy
11. Shock Therapy Exceeds Expectations In Cleaning Up Contaminated Soils

Post Your Comments:

(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio ... findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease ... hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this ...
(Date:6/28/2020)... ... , ... In an upcoming episode scheduled for the fall of 2020, Advancements ... (POCT). Check local listings for more info. , Today, the majority of testing is ... labs throughout the country. Results are then available several days later. Now, in an ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... is pleased to announce the next event in a series of TOPIQ webinars, ... The TOPIQ series of webinars was developed in response to social distancing measures ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... LEXINGTON, Mass. (PRWEB) , ... August 11, 2020 ... ... awarded $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial ... year in 2021 and 2022. The network is a consortium of academic research ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter ... of a successful study, while protecting and accessing the catheter or device post-surgery is ... from Envigo in a live webinar on Wednesday, August 5, ...
Breaking Biology Technology:
Cached News: